Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;11(6):1339-1344.
doi: 10.14336/AD.2020.1104. eCollection 2020 Dec.

Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India

Affiliations

Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India

Sankha Shubhra Chakrabarti et al. Aging Dis. .

Abstract

India has witnessed a high number of COVID-19 cases, but mortality has been quite low, and most cases have been asymptomatic or mild. In early April, we had hypothesized a low COVID-19 mortality in India, based on the concept of cross-immunity. The presence of cross-immunity is presumed to lead to a milder course of disease and allow the time necessary for the development of adaptive immunity by the body to eliminate the virus. Evidence supporting our hypothesis has started showing up. Multiple studies have shown the generation of different T cell subsets and B cells responding to epitopes of viral proteins, especially of the spike protein, as a part of adaptive immunity against SARS-CoV-2. Cross-reactive T-cells have been demonstrated in patients who have been previously exposed to endemic coronaviruses. The interplay of cross-immunity and herd immunity is apparent in the COVID-19 scenario in India from the presence of a large number of asymptomatic or mild cases, a low infection-fatality ratio and a generally flat curve of percentage positivity of cases with respect to total testing, both in periods of strict lock-down and step-wise unlocking. It seems that cross-immunity resulted in faster generation of herd immunity. Although the initial restrictive measures such as lockdown prevented the rapid spread of the outbreak, further extension of such measures and overly expensive ones such as enhanced testing in India will result in a huge burden on the health economics as well as the society. Hence, we propose a restructuring of the health services and approach to COVID-19. The restructured health services should move away from indiscriminate testing, isolation and quarantine, and instead, the emphasis should be on improving facilities for testing and management of only critical COVID cases and the replacement of complete lockdowns by the selective isolation and quarantine of susceptible persons such as the aged and those with co-morbidities. In the process of describing India-specific plans, we emphasize why the development of country-specific plans for tackling epidemics is important, instead of adopting a "one policy fits all" approach.

Keywords: T cells; hygiene hypothesis; integration; lockdown; restructuring.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests On behalf of all authors, the corresponding author states that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
The trend of COVID-19 cases in India. X-axis shows days since confirmed cases first reached 30/day (22 March 2020). Y-axis shows daily new confirmed COVID-19 cases. There is a visible decline in daily number of cases from mid-September 2020 onwards. Lockdown restriction easing started since early June 2020. The color of the trendline represents the most important statistic of percentage positivity of tests conducted daily. For a major part between day-100 and day-150, the line color is red (>10% positivity). This has come down to <5% positivity now (line color light orange), implying a general decrease in SARS-CoV-2 infections despite lifting of most lockdown restrictions.

References

    1. Chakrabarti SS, Kaur U, Banerjee A, Ganguly U, Banerjee T, Saha S, et al. (2020). COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity? Aging Dis, 11(3):480. - PMC - PubMed
    1. Murhekar M, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj J, et al. (2020). Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res, 152(1):48. - PMC - PubMed
    1. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 181(7):1489-1501.e15. - PMC - PubMed
    1. Sette A, Crotty S (2020). Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol, 20(8):457-8. - PMC - PubMed
    1. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. (2020). Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science, 370:89-94. - PMC - PubMed

LinkOut - more resources